Pharma minds, le podcast de ceux qui font la Pharma
Latest Episode

"Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare.

MFN isn't just a pricing debate. It is already changing how pharma companies think about where, when and how they launch new medicines.

In this episode of Pharma minds, I speak with Laure Nas de Tourris, Partner at Clarivate, about what she is seeing on the ground as pharma and biotech leaders start adapting their commercial strategies to the new Most Favored Nation (MFN) environment.

And one thing is clear:uncertainty is here to stay.

From early-stage assets to upcoming launches and portfoli

Play Latest Episode

Bienvenue sur Pharma minds !

Je suis Nathalie Lahitte, pharmacienne et exploratrice des grands défis de la pharma et de la santé. J’ai créé Pharma minds pour révéler les voix qui osent bousculer le secteur et imaginer son futur.

Ici, on parle de vraies histoires, de parcours audacieux et d’idées qui changent la donne. Mon but ? Casser les silos, poser les questions qui comptent et inspirer ceux qui feront la différence.

Vous voulez comprendre les enjeux, vous challenger et vous connecter à un écosystème engagé ? Vous êtes au bon endroit !

Reviews

Merci pour ce podcast passionnant

"Des entretiens agréables et instructifs à écouter, un bon rythme et un ton léger pour parler sérieusement tout en mettant à l’aise l’interlocuteur afin qu’il formule bien le fond de sa pensée. Merci …"

bglmn | Nov. 19, 2023

Un Podcast tant attendu !

"Bravo pour ce Podcast qui nous permet d’écouter des grandes voies de la Pharma, comprendre leur parcours, et trouver tout simplement l’inspiration ! Hâte de découvrir la suite !"

Septante 8 | June 1, 2023

Une immersion enrichissante et réussie dans le monde de la pharma

"Pharma Minds est un nouveau podcast a ne pas louper et qui mérite chacune de ses 5 étoiles parce que ça fait du bien un bon podcast en français, dans la bonne humeur et le tout dans un format court. …"

Cboo216 | May 23, 2023
See all reviews

Recent

MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare.
Sept. 20, 2026

MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare.

MFN isn't just a pricing debate. It is already changing how pharma companies think about where, when and how they launch new medicines. In this episode of Pharma minds, I speak with Laure Nas de Tourris, Partner at Clarivate, about what she is seeing on the ground as pharma and biotech leaders start adapting their commercial strategies to the new Most Favored Nation (MFN) environment. And one thing is clear:uncertainty is here to stay. From early-stage assets to upcoming launches and portfoli
Watch the Video
"Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare.
Sept. 20, 2026

"Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare.

MFN isn't just a pricing debate. It is already changing how pharma companies think about where, when and how they launch new medicines. In this episode of Pharma minds, I speak with Laure Nas de Tourris, Partner at Clarivate, about what she is seeing on the ground as pharma and biotech leaders start adapting their commercial strategies to the new Most Favored Nation (MFN) environment. And one thing is clear:uncertainty is here to stay. From early-stage assets to upcoming launches and portfoli
Listen to the Episode
Europe Can't Pay More For Innovation (and China Isn't Waiting)
Sept. 13, 2026

Europe Can't Pay More For Innovation (and China Isn't Waiting)

What if Europe’s answer to the rising cost of pharmaceutical innovation wasn’t simply to pay more, but to develop differently? In this episode of Pharma minds, I speak with Franck Le Deu, one of the few European voices with decades of first-hand experience inside Asia’s rapidly evolving biopharma ecosystem. Franck spent 20 years in China as a Senior Partner at McKinsey, advising some of the world’s largest pharmaceutical companies as China transformed from a market for Western medicines into a
Watch the Video
"Europe's Access Dilemma" (2/5) - Europe Can't Pay More For Innovation: The Case For Co-developing With Asia
Sept. 13, 2026

"Europe's Access Dilemma" (2/5) - Europe Can't Pay More For Innovation: The Case For Co-developing With Asia

What if Europe’s answer to the rising cost of pharmaceutical innovation wasn’t simply to pay more, but to develop differently? In this episode of Pharma minds, I speak with Franck Le Deu, one of the few European voices with decades of first-hand experience inside Asia’s rapidly evolving biopharma ecosystem. Franck spent 20 years in China as a Senior Partner at McKinsey, advising some of the world’s largest pharmaceutical companies as China transformed from a market for Western medicines into a
Listen to the Episode
💊 Dans la santé, un produit mal classé peut couler toute une activité.
Sept. 9, 2026

💊 Dans la santé, un produit mal classé peut couler toute une activité.

👉 L’épisode complet est disponible sur toutes les plateformes d’écoute mais aussi sur Youtube en suivant ce lien :   https://youtu.be/HWLSeqH8Yss
Watch the Video
Europe Is Losing Access to New Medicines. Here’s Why.
Sept. 6, 2026

Europe Is Losing Access to New Medicines. Here’s Why.

What happens when making medicines cheaper in the US makes Europe less attractive for pharmaceutical innovation? In this episode of Pharma minds, I speak with Christoffer Frendesen, a Brussels-based pharmaceutical journalist specializing in pricing and market access, about one of the most consequential questions facing Europe’s pharmaceutical market: what happens when the rules of global drug pricing change? Trump’s Most Favored Nation (MFN) policy is putting pressure on pharmaceutical prices
Watch the Video
"Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why.
Sept. 6, 2026

"Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why.

What happens when making medicines cheaper in the US makes Europe less attractive for pharmaceutical innovation? In this episode of Pharma minds, I speak with Christoffer Frendesen, a Brussels-based pharmaceutical journalist specializing in pricing and market access, about one of the most consequential questions facing Europe’s pharmaceutical market: what happens when the rules of global drug pricing change? Trump’s Most Favored Nation (MFN) policy is putting pressure on pharmaceutical prices
Listen to the Episode
⚠️ Un concurrent peut faire tomber votre produit de santé avant l'autorité.
Sept. 3, 2026

⚠️ Un concurrent peut faire tomber votre produit de santé avant l'autorité.

Ecoutez l'épisode en entier : https://youtu.be/HWLSeqH8Yss
Watch the Video
View all Episodes View all Videos